Surufatinib — a novel oral agent for neuroendocrine tumours

In two phase III trials, surufatinib, a novel oral tyrosine kinase inhibitor targeting immune cells and angiogenesis, was effective for treating pancreatic and extra-pancreatic neuroendocrine tumours. These findings further expand the therapeutic options for patients with gastro–entero–pancreatic, t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Endocrinology 2021-01, Vol.17 (1), p.9-10
Hauptverfasser:	Koumarianou, Anna, Kaltsas, Gregory
Format:	Artikel
Sprache:	eng
Schlagworte:	692/163/2743/1459/1963 692/700/565/1436 Administration, Oral Angiogenesis Cancer Clinical trials Double-Blind Method Drug therapy Endocrinology Endocrinology & Metabolism Enzyme inhibitors Humans Life Sciences & Biomedicine Medicine Medicine & Public Health Neuroendocrine tumors Neuroendocrine Tumors - drug therapy News & Views news-and-views Oncology, Experimental Pancreas Pancreatic cancer Pancreatic Neoplasms Pancreatic tumors Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Science & Technology Thymus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In two phase III trials, surufatinib, a novel oral tyrosine kinase inhibitor targeting immune cells and angiogenesis, was effective for treating pancreatic and extra-pancreatic neuroendocrine tumours. These findings further expand the therapeutic options for patients with gastro–entero–pancreatic, thymic and lung neuroendocrine tumours.
ISSN:	1759-5029 1759-5037
DOI:	10.1038/s41574-020-00439-0